Skip to content

May 2018, Volume 25, Issue 3

May’s edition of the EJHP includes an editorial on change blindness as well as original articles on individualised antimicrobial dosing in critically ill patients undergoing continuous renal replacement therapy, on the evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab) and on the impact of fampridine on quality of life. More information on the rapid acting fentanyl formulations in breakthrough pain in cancer can be found on the electronic pages of the EJHP May issue.

Read the EJHP May edition HERE

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.